Trade war, CFIUS in­ter­ven­tions force a shift in strat­e­gy at Fo­s­un — sig­nal­ing some big po­ten­tial prob­lems for US biotechs

Chi­nese biotech in­vestors are get­ting caught in a big squeeze as Pres­i­dent Don­ald Trump rais­es the stakes in an on­go­ing trade war with the Asian pow­er­house. And the fall­out could have ma­jor im­pli­ca­tions for a biotech in­dus­try that has be­come in­creas­ing­ly at­tuned to Chi­na’s am­bi­tious group of deep-pock­et­ed in­vestors.

Kevin Xie, who man­ages Fo­s­un In­ter­na­tion­al’s US strat­e­gy, tells Bloomberg that they’re turn­ing greater at­ten­tion to emerg­ing mar­kets as trade re­la­tions with the US grow in­creas­ing­ly frayed. Black­list­ing Huawei Tech­nolo­gies has played a di­rect role in that shift.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.